TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Community
Main Feed
Today's Market Intel
Top Stocks
AI-Curated Stock Lists
IPO Calendar
Upcoming Listings
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
Stock Reports
AI Research Reports
Commentary
Opinionated Stock Takes
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Account
Plan, Billing & Appearance
Log inCreate Account
← Back to TickerSpark
▌Research Report·October 30, 2026

Insmed (INSM): BRINSUPRI Launch Drives the Bull Case

Insmed is scaling quickly on the back of BRINSUPRI, with ARIKAYCE still contributing meaningful cash flow. The stock looks attractive for investors who can accept biotech execution risk, but valuation remains demanding.

Research ReportINSMHealthcareBiotechnologyBiotech
By TickerSpark·October 30, 2026·20 min read

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

Insmed (INSM): BRINSUPRI Launch Drives the Bull Case
B-
Overall
B+
Balance Sheet
B-
Income
B
Estimates
C+
Valuation
TickerSpark AI RatingBuy
▌Investment Summary
Insmed (INSM) is a Buy and earns an overall grade of B- as BRINSUPRI drives a rapid commercial ramp and ARIKAYCE continues to support the franchise. Our fair value is $125, which reflects strong launch momentum but also the company’s negative earnings, heavy cash burn, and premium valuation.

Thesis

Insmed (INSM) merits a Buy rating for a medium-term investor who can tolerate biotech execution risk. The investment case rests on a fast-scaling BRINSUPRI launch, a durable ARIKAYCE franchise, and a pipeline led by TPIP. The $125 fair value estimate reflects strong commercial momentum, but also discounts the company’s negative earnings, heavy cash burn, elevated revenue multiple, and dependence on successful regulatory and clinical execution.

BRINSUPRI generated $400.1 million in Q3 2026 revenue, up 29% sequentially, while ARIKAYCE contributed $124.4 million, up 9% year over year. Total quarterly revenue reached $524.4 million, compared with $142.3 million in Q3 2025. Insmed raised 2026 revenue guidance to $1.35 billion to $1.40 billion for BRINSUPRI and $460 million to $470 million for ARIKAYCE.

The central tension is valuation. At $97.07, INSM trades at 78.1x forward earnings and 18.1x enterprise value to revenue, even though free cash flow was negative $902.5 million for fiscal 2025. The growth outlook is substantial, with analyst estimates calling for revenue of $2.9 billion in 2027 and $6.2 billion in 2030, but the market is already charging a premium for that future. This is a strong business transition priced ahead of its income statement.

Company Overview

Insmed (INSM) is a Bridgewater, New Jersey-based biotechnology company founded in 1988. It employs 1,664 people and develops therapies for serious and rare diseases across the United States, Europe, Japan, and other international markets. Its commercial portfolio currently consists of ARIKAYCE and BRINSUPRI, supported by respiratory, pulmonary vascular, inflammatory, and gene therapy programs.

The company generated $606.4 million of revenue in 2025, compared with $363.7 million in 2024. The sharpest step-up arrived during 2026 as BRINSUPRI moved from launch investment to meaningful commercial scale. Nine-month 2026 revenue reached $1.26 billion, compared with $342.6 million in the first nine months of 2025.

▌Common Questions

Frequently asked questions

+Is INSM stock a buy right now?
Yes, INSM is a Buy for investors who can tolerate biotech execution risk. BRINSUPRI is scaling quickly, ARIKAYCE remains a durable commercial base, and the company’s overall grade of B- supports a constructive view despite the premium valuation.
+What is INSM's fair value?
Insmed’s fair value is $125. That estimate reflects BRINSUPRI’s rapid launch, ARIKAYCE’s continued contribution, and the market’s willingness to pay up for future growth, while still discounting negative earnings, heavy cash burn, and execution risk.
+Why is Insmed growing so fast?
▌The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

Creates a free TickerSpark account — newsletter included.

or with email

Daily market recap + weekly preview. One-click unsubscribe in every email.

Insmed’s business model is shifting from a single-product specialty biopharma into a multi-product respiratory company. Management expects BRINSUPRI, TPIP, and ARIKAYCE to generate more than $14 billion of combined peak sales, including estimates above $7 billion for BRINSUPRI, above $6 billion for TPIP, and above $1 billion for ARIKAYCE. Those figures are company projections, not current revenue.

Business Segment Deep Dive

Insmed reports one operating segment, but product revenue provides a clear economic split. BRINSUPRI produced $400.1 million in Q3 2026, or roughly three-quarters of quarterly revenue, while ARIKAYCE generated $124.4 million. The two products therefore represent both a growth engine and an established commercial base.

BRINSUPRI’s Q3 revenue increased from $28.1 million in Q3 2025 to $400.1 million in Q3 2026. Nine-month BRINSUPRI revenue reached $917.1 million, including $913.8 million from the United States and $3.3 million internationally. The geographic mix reflects the early stage of the Japan launch and the product’s initial concentration in the U.S.

ARIKAYCE generated $338.8 million in the first nine months of 2026, compared with $314.5 million in the prior-year period. International ARIKAYCE revenue rose 21% year over year to $130.2 million, while U.S. revenue increased 1% to $208.6 million. This pattern shows a mature U.S. franchise with continued international contribution.

Geography is becoming more important. Total Q3 2026 U.S. revenue was $473.6 million, up 364% year over year, while international revenue was $50.8 million, up 26%. Japan launched BRINSUPRI in October 2026, creating a second commercial market for the company’s fastest-growing product.

Get AI research on any stock

Instant reports, daily intelligence, and an AI analyst in your pocket.

Get Started →

Flagship Product Analysis

BRINSUPRI is the flagship asset and the primary reason Insmed’s financial profile is changing. The oral brensocatib product is approved for non-cystic fibrosis bronchiectasis and generated $400.1 million in Q3 2026. Management raised full-year 2026 BRINSUPRI revenue guidance to $1.35 billion to $1.40 billion, increasing the low end of the prior range by $100 million.

Management stated that BRINSUPRI exceeded $1 billion in revenue during its first four full quarters of launch and reached blockbuster status. The company also reported strength in payer approval rates, reauthorization rates, persistence, and dispenses. These indicators support the view that the launch is moving beyond initial prescription activity toward recurring treatment.

Japan adds a distinct expansion opportunity. BRINSUPRI is the first and only approved medicine for bronchiectasis in Japan, where Insmed cites approximately 150,000 diagnosed patients. In the phase 3 ASPEN study, Japanese patients recorded a 68% reduction in annualized exacerbation rates, compared with approximately 20% in the global study. The Japanese launch therefore combines regulatory exclusivity with unusually strong reported clinical results.

The product’s risk is not demand creation alone. Insmed must sustain payer access, physician education, treatment persistence, and manufacturing capacity while broadening diagnosis. The BEST-BE observational study plans to enroll 1,000 U.S. adults across 13 sites, while an EMBARC study plans to follow up to 3,000 European patients for three years. Those studies can strengthen the long-term evidence base for BRINSUPRI.

Innovation & Competitive Advantage

Insmed’s strongest competitive advantage is the combination of commercial focus and clinical optionality. BRINSUPRI established a first-mover position in bronchiectasis, ARIKAYCE has a long commercial history in refractory MAC lung disease, and TPIP is advancing through a four-study phase 3 program.

TPIP is a once-daily inhaled treprostinil prodrug being studied in pulmonary hypertension associated with interstitial lung disease, pulmonary arterial hypertension, progressive pulmonary fibrosis, and idiopathic pulmonary fibrosis. The PALM-ILD study was more than 35% enrolled, PALM-PAH had enrolled its first patient, and the PALM-PPF study had initiated its first site by Q3 2026. The company expects PALM-IPF to begin in the first half of 2027.

The earlier pipeline includes INS1033, INS1148, INS1201 for Duchenne muscular dystrophy, and INS1202 for amyotrophic lateral sclerosis. Insmed expects phase 1 data from its DMD and ALS gene therapy programs in 2027 and has reiterated a goal of submitting one to two investigational new drug applications annually through the end of the decade.

The moat is strongest where regulatory status and specialist relationships reinforce each other. Insmed has an established commercial organization in respiratory medicine, an approved product in bronchiectasis, and a second product with a potential expanded label. The counterweight is that TPIP and the early research programs remain clinical assets rather than commercial earnings.

Operations & Supply Chain

Insmed is scaling commercial operations at the same time it is expanding clinical development. Q3 2026 research and development expense was $270.0 million, while selling, general, and administrative expense was $253.0 million. Combined operating expenses increased 40% year over year as the company supported the BRINSUPRI launch and funded its pipeline.

The company has added targeted infrastructure for diagnosis and physician education. A disease educator program deployed an initial team of 16 nurses across the United States to work with pulmonologists treating high concentrations of COPD and asthma patients. Insmed is also developing AI-powered diagnostic tools with strategic partners to help identify possible bronchiectasis cases in existing medical records.

Supply concentration is a material operating risk. Insmed’s commercial supply of ARIKAYCE and BRINSUPRI is manufactured in Canada, while TPIP depends on a single supplier in Taiwan. A disruption at either location could affect product availability or clinical timelines. The company’s 1,664 employees and expanding product portfolio also increase the need for disciplined quality, regulatory, and inventory management.

Gross margin provides an encouraging operating signal. Q3 2026 cost of product revenue was $78.2 million, or 14.9% of revenue, compared with 20.6% in Q3 2025. Management attributed the improvement to the favorable contribution of BRINSUPRI, which has lower manufacturing costs than ARIKAYCE.

Market Analysis

Insmed is targeting specialized respiratory markets where diagnosis, treatment persistence, and reimbursement matter as much as total patient count. Management estimates approximately 500,000 diagnosed bronchiectasis patients in the United States and cites a potential several-million-patient opportunity when undiagnosed bronchiectasis among COPD and asthma populations is included.

The company estimates that approximately 32 million U.S. patients have COPD or asthma. If a single-digit percentage of that population has undiagnosed bronchiectasis, the addressable opportunity for BRINSUPRI would expand materially beyond the diagnosed population. The company’s current peak sales estimate above $7 billion excludes this comorbid opportunity.

ARIKAYCE offers a second market expansion path. The current U.S. and Japan opportunity is estimated at approximately 15,000 patients in each region, while a broader label could expand the addressable population to more than 100,000 patients in each market. The combined potential market would exceed 200,000 patients if both regulatory expansions succeed.

TPIP adds exposure to pulmonary hypertension and fibrosis. Insmed cites patient pools across PAH, PH-ILD, progressive pulmonary fibrosis, and IPF in the United States, Europe, and Japan, with a company peak sales estimate above $6 billion across four indications. The market opportunity is large, but the revenue is several years behind BRINSUPRI and depends on phase 3 outcomes.

Like what you're reading?

Get full access to AI-powered research reports, market analysis, and portfolio tools.

Get Started →

Customer Profile

The primary customers are pulmonologists, specialty pharmacies, hospitals, and payers. BRINSUPRI’s growth depends on finding patients with bronchiectasis, securing authorization, and maintaining treatment over time. Insmed’s reported strength in payer approvals, reauthorizations, persistence, and dispenses directly addresses those commercial requirements.

Patients with COPD or asthma are an important secondary customer pool because persistent respiratory symptoms can support additional bronchiectasis evaluation. Insmed’s 16-nurse educator program, retrospective imaging work at three U.S. centers, and partnership with the American Thoracic Society are designed to improve recognition of the disease.

Japan is an especially important international customer market. Insmed cites approximately 150,000 diagnosed bronchiectasis patients in Japan and has secured favorable pricing after reporting stronger ASPEN results among Japanese patients. ARIKAYCE also generated $48.9 million of international revenue in Q3 2026, demonstrating an existing overseas commercial channel.

Reimbursement remains a central customer risk. For ARIKAYCE, the Inflation Reduction Act’s small-manufacturer provision increases Insmed’s Medicare catastrophic coverage contribution to 5% in 2027, with annual increases continuing toward 20% in 2031. That change will pressure gross-to-net economics even if unit demand remains healthy.

Competitive Landscape

ARIKAYCE competes against standard antibiotic combinations used in MAC lung disease, as well as developing anti-infective therapies. Its strategic advantage is regulatory specificity: ARIKAYCE is the only FDA-approved therapy specifically identified for refractory MAC lung disease. The pending supplemental application targets a broader treatment population and carries a January 28, 2027 FDA action date.

BRINSUPRI entered a less established but increasingly competitive bronchiectasis market. It was the first and only FDA-approved treatment for non-cystic fibrosis bronchiectasis at its August 2025 approval and is also the first and only approved treatment in Japan. Competing DPP1 programs include florensocatib and verducatib, while supportive care and symptom management remain part of current treatment practice.

The company also competes for specialist attention and capital against larger respiratory franchises, including products such as Dupixent, Tezspire, Fasenra, and Winrevair. Management states that BRINSUPRI’s launch-aligned quarterly revenue has exceeded those products during comparable launch periods. That comparison supports launch execution, although it does not eliminate the need to build long-term treatment durability.

TPIP faces competition in pulmonary hypertension and interstitial lung disease from established inhaled prostanoid products and other clinical programs. Insmed’s stated differentiation is once-daily dosing, improvements in six-minute walk distance and pulmonary vascular resistance, and a favorable safety and convenience profile. Those claims remain tied to clinical development and future regulatory decisions.

Macro & Geopolitical Landscape

Policy is a direct financial factor for Insmed. The Inflation Reduction Act increases the company’s share of Medicare catastrophic coverage costs for ARIKAYCE from 1% in 2026 to 5% in 2027, with the contribution rising annually toward 20% in 2031. This creates a known margin headwind for an established product even as ARIKAYCE revenue grows.

The broader biotech environment favors assets with clinical proof and commercial traction. Deloitte’s 2026 life sciences outlook reports that 78% of executives expect AI to play a central role in major change, while 41% identify improved R&D productivity as their top cost-management priority. Insmed’s AI diagnostic partnerships and stated goal of submitting one to two INDs per year fit that industry direction.

International supply adds geopolitical exposure. Commercial ARIKAYCE and BRINSUPRI supply is manufactured in Canada, and TPIP relies on a single supplier in Taiwan. The geographic concentration does not establish an immediate disruption, but it makes supplier qualification, inventory planning, and regulatory coordination important parts of the investment case.

Capital markets also reward certainty unevenly across biotechnology. Insmed’s positive 30-day news sentiment score of 0.9 and improving 90-day score of 0.9 show strong market enthusiasm, while the FMP rating of C- reflects weak current profitability and valuation measures. The split is a useful reminder that favorable news flow and attractive financial valuation are different things.

Balance Sheet Health

▌Premium Members Only

Cash burn remains heavy, with free cash flow negative $902.5 million in fiscal 2025 even as revenue surged to $524.4 million in Q3 2026.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Income Statement Strength

▌Premium Members Only

Q3 2026 revenue jumped to $524.4 million from $142.3 million a year earlier, led by BRINSUPRI’s $400.1 million contribution.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Estimates Outlook

▌Premium Members Only

Management lifted 2026 BRINSUPRI guidance to $1.35 billion-$1.40 billion and ARIKAYCE guidance to $460 million-$470 million.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Valuation Assessment

▌Premium Members Only

At $97.07, INSM trades at 78.1x forward earnings and 18.1x EV/revenue despite negative fiscal 2025 free cash flow.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Target Prices & Recommendation

▌Premium Members Only

The report’s fair value is $125, with upside tied to BRINSUPRI scaling and downside tied to execution risk and a rich revenue multiple.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Closing

Insmed (INSM) has crossed an important threshold: it is no longer valued solely as a development-stage biotech. BRINSUPRI generated $400.1 million in Q3 2026, ARIKAYCE added $124.4 million, and management raised full-year guidance for both products. The company is building a respiratory franchise with commercial revenue, regulatory optionality, and a deep clinical pipeline.

The investment case still demands patience. Fiscal 2025 free cash flow was negative $902.5 million, the latest earnings history shows only two beats in eight quarters, and the stock trades at 78.1x forward earnings and 18.1x enterprise value to revenue. BRINSUPRI must sustain its launch, ARIKAYCE must defend its franchise, and TPIP must convert clinical progress into approvals.

The balance of evidence favors measured participation rather than aggressive positioning. A $125 fair value estimate and Buy rating capture the company’s unusual combination of near-term commercial momentum and long-term pipeline potential, while recognizing that the market has already paid for much of the story. For a medium-term investor, execution remains the engine and valuation remains the speed limit.

Growth is being driven primarily by BRINSUPRI, which generated $400.1 million in Q3 2026 and rose 29% sequentially. ARIKAYCE added $124.4 million in the quarter, and total revenue reached $524.4 million versus $142.3 million a year earlier.
+What are the biggest risks for INSM?
The biggest risks are valuation, cash burn, and execution. INSM traded at 78.1x forward earnings and 18.1x EV/revenue, while fiscal 2025 free cash flow was negative $902.5 million, so the stock needs continued commercial and regulatory success to justify the premium.
+How important is BRINSUPRI to the investment case?
BRINSUPRI is the core of the investment case because it produced $400.1 million in Q3 2026 and management raised 2026 guidance to $1.35 billion-$1.40 billion. The launch is also expanding into Japan, where the drug is the first approved bronchiectasis medicine and could add another growth leg.
▌For Active Investors

Want Reports Like This on Any Stock?

Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.

Get Full Access →

Not ready to subscribe? ·

▌For Active Investors

Stock research for every investor

  • Reports on any stock
  • Daily market intelligence
  • AI analyst in your pocket
  • Portfolio analysis tools
Get Full Access →

Cancel anytime

▌The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, free in your inbox.

Creates a free TickerSpark account — newsletter included.

or with email

Daily market recap + weekly preview. One-click unsubscribe in every email.

▌More on INSM

More to read

All articles
Insmed Incorporated (INSM) spikes 20% on Sanofi deal buzz
INSM

Insmed Incorporated (INSM) spikes 20% on Sanofi deal buzz

Insmed Incorporated (INSM) spikes after reports that Sanofi is weighing a possible acquisition, driving heavy volume and a volatility halt. The move comes as strong revenue growth and raised guidance add support to the biotech’s valuation, even as profitability remains uneven.

Nov 20·5 min
Insmed Incorporated (INSM) jumps 18.4% on Sanofi takeover buzz
INSM

Insmed Incorporated (INSM) jumps 18.4% on Sanofi takeover buzz

Insmed Incorporated (INSM) jumps after a Bloomberg report said Sanofi is weighing an acquisition and has spoken with advisers. The move came on heavy volume and reflects rising takeover speculation around the biotech’s commercial products and late-stage pipeline.

Nov 19·5 min
Insmed Incorporated (INSM) climbs 13.9% on Q3 beat
INSM

Insmed Incorporated (INSM) climbs 13.9% on Q3 beat

Insmed Incorporated (INSM) climbs after a strong third-quarter report, higher 2026 revenue guidance, and accelerating BRINSUPRI sales. The biotech’s commercial momentum is improving, but investors are still weighing negative earnings, valuation risk, and whether the extended-hours move holds in regular trading.

Oct 29·5 min